[Target population and predictive factors of survival and efficacy of anti-HER1/EGFR drugs].
Cadranel
Jacques
J
Service de pneumologie, Hôpital Tenon, 4, rue de la Chine, 75020 Paris.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001984:Bronchial Neoplasms / Q000188:drug therapy / Q000378:metabolism; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D047428:Protein Kinase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors